Literature DB >> 12227712

Role of signal-averaged electrocardiograms for predicting the inducibility of ventricular fibrillation in the syndrome consisting of right bundle branch block and ST segment elevation in leads V1-V3.

Riko Masaki1, Ichiro Watanabe, Toshiko Nakai, Kazuhiko Kondo, Naohiro Oshikawa, Hidezou Sugimura, Kimie Okubo, Toshiaki Kojima, Satoshi Saito, Yukio Ozawa, Katsuo Kanmatsuse.   

Abstract

Right bundle branch block and ST segment elevation (RBBB-STE) in the right precordial leads have been reported as a distinct clinical and electrocardiographic syndrome in patients prone to ventricular fibrillation (VF) in the absence of structural heart disease (Brugada syndrome). The purpose of the study was to investigate the role of signal averaged electrocardiogram (SAECG) in identifying patients at high risk among asymptomatic RBBB-STE patients. Thirteen patients with the RBBB-STE ECG were identified. Symptoms were: syncope (n=3, cases 1, 3, and 11), atypical chest pain (n=3, cases 4, 10, and 12) and palpitations (n=2, cases 6, and 7). The other 5 patients were asymptomatic. SAECG and programmed electrical stimulation (PES) were conducted in all patients. Body surface late potentials (LPs) were present in 7 of 13 patients before PES. Vf was induced in 6 of 7 LP positive patients. Vf was induced in 3 of 6 LP negative patients, but LP became positive in 2 of 3 patients in whom Vf was induced. One patient with syncope due to VF (case 1), 1 patient without symptoms who died suddenly during follow up (case 2), and 1 asymptomatic patient (case 9) showed reproducibly positive LP. In a patient (case 9) with positive LP at baseline, LP transiently became negative during follow up. In RBBB-STE patients, reproducibly positive LP is at risk for malignant ventricular arrhythmias and sudden death. Repeated SAECG recording may be useful for screening high-risk patients who should receive electrophysiological study among asymptomatic RBBB-STE patients.

Entities:  

Mesh:

Year:  2002        PMID: 12227712     DOI: 10.1536/jhj.43.367

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  6 in total

1.  Sodium channel blockers enhance the temporal QT interval variability in the right precordial leads in Brugada syndrome.

Authors:  Tetsuzou Kanemori; Hiroki Shimizu; Katsumi Oka; Yoshio Furukawa; Kenji Hiromoto; Takanao Mine; Tohru Masuyama; Mitsumasa Ohyanagi
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

2.  Brugada syndrome: Controversies in Risk stratification and Management.

Authors:  Lm Nunn; J Bhar-Amato; Pd Lambiase
Journal:  Indian Pacing Electrophysiol J       Date:  2010-09-05

3.  Identifying patterns of spatial current dispersion that characterise and separate the Brugada syndrome and complete right-bundle branch block.

Authors:  A Kandori; W Shimizu; M Yokokawa; T Noda; S Kamakura; K Miyatake; M Murakami; T Miyashita; K Ogata; K Tsukada
Journal:  Med Biol Eng Comput       Date:  2004-03       Impact factor: 2.602

Review 4.  Risk factors for cardiac events in patients with Brugada syndrome: A PRISMA-compliant meta-analysis and systematic review.

Authors:  Wenqing Wu; Li Tian; Jinshan Ke; Yi Sun; Ruixia Wu; Jianfang Zhu; Qinmei Ke
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

5.  Atrial electrical abnormality in patients with Brugada syndrome assessed by signal-averaged electrocardiography.

Authors:  Yasutsugu Nagamoto; Yuto Fujii; Yuichi Morita; Yusuke Ueda; Yasuko Miyake; Kenichi Yamane; Mai Fujiwara; Shinji Mito; Yuichiro Watari; Hiromichi Tamekiyo; Tomokazu Okimoto; Yuji Muraoka; Yasuhiko Hayashi
Journal:  Indian Heart J       Date:  2017-05-23

6.  Gender Differences in Prognosis and Risk Stratification of Brugada Syndrome: A Pooled Analysis of 4,140 Patients From 24 Clinical Trials.

Authors:  Mengchen Yuan; Chao Tian; Xinye Li; Xinyu Yang; Xiaofeng Wang; Yihan Yang; Nian Liu; Kengo F Kusano; Hector Barajas-Martinez; Dan Hu; Hongcai Shang; Yonghong Gao; Yanwei Xing
Journal:  Front Physiol       Date:  2018-08-22       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.